FGF19 and metabolic dysfunction-associated steatotic liver disease: In T2D and NAFLD, FXR signaling can be dysregulated; for instance, circulating FGF19 concentrations are often lower in patients with NAFLD, permitting unchecked bile acid synthesis and potential accumulation of toxic species [126].